Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTT: Oxygen Therapy in COPD with Moderate Desaturation
NCT00692198Phase 3
Key facts
- Status
- Completed
- Start
- Jan 2009
- Primary completion
- Aug 2015
- Countries
- 1
- Sponsor
- National Heart, Lung, and Blood Institute
- Modality
- Inhalation Devices
- Drugs
- oxygen
- Conditions
- chronic obstructive pulmonary disease (COPD)
01
Overview
Phase 3, randomised, open-label trial of oxygen in chronic obstructive pulmonary disease (COPD), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Death or Hospitalization, Whichever Occurs First at 18.4 months. Started Jan 2009; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients aged 40+ with COPD, MMRC dyspnea >= 1, and moderate desaturation (resting SpO2 89-93% or exercise SpO2 < 90%).
04
Endpoints
Primary
Death or Hospitalization, Whichever Occurs First
Secondary
Death
Beyond the preview
Go deeper on NCT00692198.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00692198.